Effects of Decohexaenoic Acid Supplementation on Markers of Inflammatory Muscle Damage

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-01

Study Completion Date

2016-12-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized, placebo-controlled, double-blind, placebo-controlled clinical trial consisting of 15 triathletes in which it is intended to observe less inflammatory damage at the muscular level after performing eccentric exercises.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Influence of Caffeinated and Non-caffeinated Pre-workout Supplements on Resistance Exercise Performance

NCT04712578

Resistance Training Caffeine Dietary Supplements

COMPLETED NA

Nutritional Supplement, Eccentric Exercise and Recovery

NCT01444170

Injury Inflammation

COMPLETED PHASE1/PHASE2

The Short Term Effects of Oceanix Supplementation on Recovery

NCT04315077

Oxidative Stress Muscle Strength Resistance Training +2 more

COMPLETED NA

Antioxidants Vitamins and Muscle Damage

NCT05127928

Oxidative Stress

COMPLETED NA

The Effects of 10 Days of Extreme Endurance on Performance

NCT03337737

Human Performance

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sport

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

experimental group

Group Type EXPERIMENTAL

supplement consumption

Intervention Type DIETARY_SUPPLEMENT

Composition of the Experimental Product: Concentrated oil of Tridocosahexaenoin-AOX® \* (350 mg per capsule), α-tocopherol and coating agent (gelatin). Each capsule is 700 mg, of which 500 mg is oil.

Placebo composition: Olive oil (each capsule is 700 mg).

Number of capsules: 6 per day, for any of the two products. The dose taken daily is 2.1 g / day for DHA.

Supplementation Period: Each group completed two 10-week consumption periods for each of the products, with an intermediate washing period of 4 weeks (28 days).

control group

Group Type PLACEBO_COMPARATOR

supplement consumption

Intervention Type DIETARY_SUPPLEMENT

Composition of the Experimental Product: Concentrated oil of Tridocosahexaenoin-AOX® \* (350 mg per capsule), α-tocopherol and coating agent (gelatin). Each capsule is 700 mg, of which 500 mg is oil.

Placebo composition: Olive oil (each capsule is 700 mg).

Number of capsules: 6 per day, for any of the two products. The dose taken daily is 2.1 g / day for DHA.

Supplementation Period: Each group completed two 10-week consumption periods for each of the products, with an intermediate washing period of 4 weeks (28 days).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

supplement consumption

Composition of the Experimental Product: Concentrated oil of Tridocosahexaenoin-AOX® \* (350 mg per capsule), α-tocopherol and coating agent (gelatin). Each capsule is 700 mg, of which 500 mg is oil.

Placebo composition: Olive oil (each capsule is 700 mg).

Number of capsules: 6 per day, for any of the two products. The dose taken daily is 2.1 g / day for DHA.

Supplementation Period: Each group completed two 10-week consumption periods for each of the products, with an intermediate washing period of 4 weeks (28 days).

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male sex.
* Age: between 18 and 45 years.
* BMI ≤ 35 Kg / m2.
* Volunteers capable of understanding the clinical study, competent to grant written informed consent and willing to comply with the study procedures and requirements.
* Subjects who do not suffer from chronic diseases.
* Non-smoking subjects or less than 10 cigarettes a day.
* Subjects who have not consumed any type of NSAID within 48 hours prior to the study or during its development.
* Subjects without a history of administration of corticosteroids the previous month or during the study.
* Subjects without allergy to any of the products under investigation.
* Patients who have not modified their habits in the performance of physical activity during the study (injuries, injuries ...).
* Patients who have not modified their dietary habits during the previous month or intend to do so during the study.

Exclusion Criteria

* Subjects who do not consume medication or nutritional supplements with antioxidant and / or anti-inflammatory properties.
* Subjects who do not consume diets with abundant antioxidant and / or anti-inflammatory products.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes